Extensions of Health Economic Evaluations in R for Microsoft Excel Users: A Tutorial for Incorporating Heterogeneity and Conducting Value of Information Analyses-Reference-Cited by-同舟云学术

Extensions of Health Economic Evaluations in R for Microsoft Excel Users: A Tutorial for Incorporating Heterogeneity and Conducting Value of Information Analyses

Published:2022-11-28 Issue:1 Volume:41 Page:21-32
ISSN:1170-7690
Container-title:PharmacoEconomics
language:en
Short-container-title:PharmacoEconomics

Author:

Naylor Nichola R.^ORCID,Williams Jack^ORCID,Green Nathan,Lamrock Felicity,Briggs Andrew

Publisher

Springer Science and Business Media LLC

Subject

Public Health, Environmental and Occupational Health,Health Policy,Pharmacology

Link

https://link.springer.com/content/pdf/10.1007/s40273-022-01203-0.pdf

Reference22 articles.

1. Incerti D, Thom H, Baio G, Jansen JP. R you still using excel? the advantages of modern software tools for health technology assessment. value Health. 2019;22(5):575–79.

2. Baio G, Heath A. When simple becomes complicated: why excel should lose its place at the top table. Glob. Reg Health Technol. Assess. 2017;4(1):grhta-5000247.

3. Hollman C, Paulden M, Pechlivanoglou P, McCabe C. A comparison of four software programs for implementing decision analytic cost-effectiveness models. PharmacoEconomics. 2017;35(8):817–30.

4. Nathan Green N, Lamrock F, Naylor NR, Williams J, Briggs A. Health economic evaluation using Markov models in R for microsoft excel users: a tutorial (2022, submitted).

5. Briggs A, Sculpher M, Dawson J, Fitzpatrick R, Murray D, Malchau H. The use of probabilistic decision models in technology assessment: the case of total hip replacement. Appl Health Econ Health Policy. 2004;3(2):79–89.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in Addressing Patient Heterogeneity in Economic Evaluation: A Review of the Methods Literature;PharmacoEconomics;2024-04-27

2. Barriers and Facilitators of Using R for Decision Analytic Modeling in Health Technology Assessment: Focus Group Results;PharmacoEconomics;2024-04-12

3. Central Venous Access Devices for the Delivery of Systemic Anticancer Therapy: An Economic Evaluation;Value in Health;2024-01